Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Semaglutide, sold under the brand names Wegovy, Ozempic, and Rybelsus, has surged in popularity since it was approved by the FDA as a treatment for obesity in 2022
Tirzepatide (Zepbound) is FDA-approved for moderate-to-severe OSA in adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia)
In many APAC markets where healthcare spending is largely out of pocket, adoption tends to be slower, explains FMCG consultant Veena Giridhar-Gopal, adding that the demand profile has traditionally differed from that of western markets
regulators first approved the drug in 2017 to treat diabetes, it has become highly sought after for its appetite-stifling effects and weight-loss benefitsbut it has its trade-offs
Cutting protocol considerations: Start titration 4-8 weeks before your target cut begins so you are at working dose when the serious deficit starts Set a caloric floor below which you will not drop regardless of how suppressed your appetite becomes
US$ 28.94
US$ 22.69
US$ 24.33
